In 2019, Novartis generated 0.1 Mt of hazardous waste, which is posing a threat to the environment
Negligence in pharmaceutical waste management may lead to pollution due to pharmaceutical components near manufacturing sites1. Management of pharmaceutical waste is a critical issue globally7. Pharmaceutical waste can impact the environment significantly3. This waste may be responsible for the spread of drug-resistant bacteria1. About 700,000 people die due to drug-resistant diseases annually across the globe2.
Novartis’ chronic myeloid leukemia drug, Tasigna, caused 3,100 deaths from 2007 to 2019
In Europe and the US, about 328,000 people die from prescription drugs every year3. According to an estimate, about 412,000 people globally will be diagnosed with all types of leukemia by 20204;p1. Of which, 10–15% of the cases are attributed to chronic myeloid leukaemia (CML)4;p1. In the US alone, about 51,500 people are affected by CML4;p1.
In 2018, Novartis consumed over 4.46 billion KWh of energy; only 17.5% were from renewable sources
In 2018, the global energy consumption accounted for 179 trillion KWh2;p19 and the CO2 emissions from non-renewable sources were 33.1 gigatonnes CO2e1. Non-renewable energy sources release methane, CO2, and other harmful gases into the environment3. Methane is a powerful greenhouse gas and is 84 times more potent than CO24.
In 2018, Novartis’ emitted over 6M tCO2e; equal to 11.67% of the global pharma industry emissions
The cumulative GHG emissions in 2019 accounted for over 52 billion tonnes CO2e1. The rise in Earth’s surface temperature is responsible for hotter waves, heavier rainfall, powerful hurricanes, and more frequent droughts3. The pharmaceutical industry on average emits about 52 million tCO2e each year2.